DIAGNOSIS OF MEDULLARY THYROID CANCER


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Medullary thyroid cancer is more frequently identified in its Stages III and IV although effective treatment is possible only for a circumscribed thyroid process. It is necessary to maximally optimize the diagnosis of this pathology by currently available highly informative examination methods.

Full Text

Restricted Access

About the authors

D. Gazizova

Endocrinology Research Center

Email: daria.gazizova@gmail.com
Moscow

D. Beltsevlch

Endocrinology Research Center

MD Moscow

References

  1. Cai S., Liu H., Li W. et al. Ultrasonographic features of medullary thyroid carcinoma and their diagnostic values // Chin. Med. J. - 2010; 123 (21): 3074-8.
  2. Chambon G., Alovisetti C., Idoux-Louche C. et al. The Use of Preoperative Routine Measurement of Basal Serum Thyrocalcitoninin Candidates for Thyroidectomy due to Nodular Thyroid Disorders: Resultsfrom 2733 Consecutive Patients // J. Clin. Endocrinol. Metab. - 2011; 96 (1): 75-81.
  3. Chang T., Wu S., Hsiao Y. Medullary thyroid carcinoma: pitfalls in diagnosis by fine needleaspiration cytology and relationship of cytomorphology to RET proto-oncogenemutations // Acta Cytolog. - 2005; 49: 477-82.
  4. Cheung K., Roman S., Wang T. et al. Calcitonin measurementin the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis // J. Clin. Endocrinol. Metab. - 2008; 93: 2173-80.
  5. Ciampi R., Mian С., Fugazzola L. et al. Evidence of a Low Prevalence of RAS Mutations in a Large Medullary Thyroid Cancer Series // Thyroid. - 2013; 23 (1): 50-7.
  6. Elisei R., Bottici V., Luchetti F. et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders // J. Clin. Endocrinol. Metab. - 2004; 89: 163-8.
  7. Elisei R., Lorusso L., Romei C. et al. Medullary thyroid cancer secreting carbohydrate antigen 19-9 (Ca 19-9): a fatal case report // J. Clin. Endocrin. Metab. - 2013; 1940.
  8. Elisei R., Romei C. Calcitonin estimation in patients withnodular goiter and its significance for earlydetection of MTC: European Comments to Theguidelines of the American Thyroid Association // Thyroid Research. - 2013, 6 (1): 2.
  9. Gharib H., Papini E., Paschke R. et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules // Endocrinepractise. - 2010; 16 (1): 1-43.
  10. Hundahl S., Fleming I., Fremgen A. et al. A National Cancer Data Basereporton 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 // Cancer. - 1998; 83: 2638-48.
  11. Kloos R., Eng Ch., Evans D. et al. Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association // Thyroid. - 2009; 19 (6): 565-612.
  12. Pillarisetty V., Katz S., Ghossein R. et al. Micromedullary Thyroid Cancer: How Micro Is Truly Micro? // Ann. Surg. Oncol. - 2009; 16: 2875-81.
  13. Romei C., Pardi E., Cetani F. et al. Genetic and clinical features of multiple endocrine neoplasia types 1 and 2 // J. Oncol. - 2012; 2012: 32-47.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Russkiy Vrach Publishing House